Lazertinib is a third-generation EGFR tyrosine kinase inhibitor used for the treatment of patients with non-small cell lung cancer harboring specific EGFR mutations. To ensure safety and therapeutic efficacy,… Read more





















Lazertinib is a third-generation EGFR tyrosine kinase inhibitor used for the treatment of patients with non-small cell lung cancer harboring specific EGFR mutations. To ensure safety and therapeutic efficacy, pharmaceutical laboratories rely on a precise inventory of related compounds for analytical testing. This collection includes Lazertinib reference standards, process-related impurities, degradation products, and stable isotope labelled compounds. These materials are essential for rigorous impurity profiling, method validation, and quality control, enabling researchers to detect, quantify, and characterize potential contaminants throughout the drug development lifecycle. By utilizing these characterized standards, analysts can perform comprehensive forced degradation studies and satisfy regulatory requirements in accordance with ICH guidelines. These compounds provide the necessary analytical foundation for verifying the quality and stability of Lazertinib during all stages of pharmaceutical manufacturing.